Twitter | Search | |
Janet Freeman-Daily
Writer, speaker, science geek, lung cancer patient/activist. Chat mod, co-founder, & alum, aerospace systems engineer (retd)
16,566
Tweets
1,616
Following
4,671
Followers
Tweets
Janet Freeman-Daily May 20
Replying to @n8pennell
Making slides for presentations be like ...
Reply Retweet Like
Janet Freeman-Daily retweeted
Nathan A. Pennell MD, PhD May 19
I think this is or should be one of the primary focuses of research and policy right now, broadly applying what we already know about testing and treatment to everyone who could benefit.
Reply Retweet Like
Janet Freeman-Daily retweeted
David Juurlink May 18
I'd like to share some reflections on the death of a patient. I’ve thought about her a lot. She gave me explicit consent to tweet the details of her case, about four hours before she died. Her hope was that someone might benefit from her experience. /1
Reply Retweet Like
Janet Freeman-Daily retweeted
David Juurlink May 18
Replying to @DavidJuurlink
We all die eventually. This patient helped me realize that when my time comes, I'll be fortunate if MAiD is an option. And I will always be thankful to her, her family, and a very skilled colleague for helping me appreciate just how good a “good death” can be. / end
Reply Retweet Like
Janet Freeman-Daily May 19
Excellent piece on how “battle” metaphors might actually get in the way of helping patients achieve their true goals.
Reply Retweet Like
Janet Freeman-Daily retweeted
Alexander Drilon MD Apr 11
Punchline. TRK inhibitors are highly active in TRK fusion-positive NCLCs. Responses are durable. CNS activity is observed. It is important to include TRK fusion screening as part of comprehensive profiling of NSCLCs.
Reply Retweet Like
Janet Freeman-Daily retweeted
Robert C. Doebele May 15
Replying to @rdoebele
100% ORR for entrectinib in fusion positive pediatric cancers. Entrectinib produced striking, rapid, and durable responses in all children with refractory CNS and solid tumors harboring NTRK1/2/3, ROS1, or ALK fusions (11 out of 11), as well as in an ALK-mutated neuroblastoma.
Reply Retweet Like
Janet Freeman-Daily May 18
When cancer that has developed resistance to drug (e.g., ALK+ NSCLC develops resistance to TKI crizotinib), “wild type” can refer to ALK gene fusion BEFORE TKI treatment, and “mutated” can refer to ALK gene fusion AFTER crizotinib resistance mutations changed it.
Reply Retweet Like
Janet Freeman-Daily May 18
From dictionary: “Wild-type gene” is “A term used to describe a gene when it is found in its natural, non-mutated (unchanged) form.” Example: healthy cells have “wild-type” EGFR genes. Cancer driven by EGFR mutation has mutated (not wild type) EGFR gene.
Reply Retweet Like
Janet Freeman-Daily retweeted
Christine Lovly May 18
“Use of upfront NGS testing in patients with mNSCLC was associated with substantial cost savings and shorter time-to-test results for both CMS and commercial payers.” thank you and your team for this important work!
Reply Retweet Like
Janet Freeman-Daily retweeted
The Big Bang Theory May 16
"I would just like to take this moment to say to all the young girls out there who dream about science as a profession: Go for it. It is the greatest job in the world. And if anybody tells you you can't, don't listen."
Reply Retweet Like
Janet Freeman-Daily retweeted
The Big Bang Theory May 16
It all ended with a Big Bang. ❤️
Reply Retweet Like
Janet Freeman-Daily May 17
Replying to @ES_SCLC @theNCI
Despite extensive efforts, NSCLC produced few new treatments until 2011–then the dam burst. Hope the SCLC dam bursts soon!
Reply Retweet Like
Janet Freeman-Daily retweeted
#LCSM Chat May 17
Failure to access appropriate targeted therapy is ongoing frustration for NTRK and other oncogene-driven patients. Wish all labs would provide our contact info to patients along with molecular test results.
Reply Retweet Like
Janet Freeman-Daily retweeted
The ROS1ders May 16
"The ROS1ders Interview Dr. Ross Camidge" via Zoom Webinar on the burning questions of experienced patients. Thanks to for their technical assistance!
Reply Retweet Like
Janet Freeman-Daily retweeted
Nicole Kuderer May 16
If you are involved in advising cancer research studies, above is key data to be aware of re the recommendations to broaden eligibility criteria:
Reply Retweet Like
Janet Freeman-Daily retweeted
Nicole Kuderer May 14
3/ Broadening Criteria: ASCO-Friends submission of recommended language to FDA – regarding brain mets, organ dysfunction, minimal age, HIV (and more is in the works!):
Reply Retweet Like
Janet Freeman-Daily retweeted
Nicole Kuderer May 14
Reply Retweet Like
Janet Freeman-Daily retweeted
Nicole Kuderer May 14
1/ Congrats for herculean effort to broaden trial by and (Friends of Cancer Research) & key individuals involved! Key for pt trial access. Big Kudos also to for issuing draft guidance based on below publiations:
Reply Retweet Like
Janet Freeman-Daily retweeted
H. Jack West, MD May 16
For BRAF, vemurafenib shows marked disparity of activity for V600E vs. other, non-V600 mutations. Unfortunately, in practice, too many oncs generalize that a BRAF non-V600 mutation is "close enough" to give a BRAF mutation -- a bad extrapolation.
Reply Retweet Like